In parts of DRC, many children with severe #malaria still reach care far too late or not at all. A new #SEMAReACT study explores why, by listening to mothers and mapping how they recognize symptoms and navigate barriers to care 👉bit.ly/4bMXzff
The landscape for relapsing #malaria treatment has transformed in recent years, due in part to the achievements of PAVE. By combining new tools with real-world evidence, PAVE has helped enable adoption and rollout in countries where relapsing malaria remains a major challenge.
MMV & @deepmirror.bsky.social have launched dd4gh, an open-access AI platform giving researchers in LMICs access to advanced drug discovery tools. Designed to reduce costs & timelines, dd4gh is levelling the playing field for all scientists shaping research into #malaria & other diseases.
MMV and partners are advancing 3 AI-powered projects to tackle key #malaria challenges in drug discovery and development.
From resistance and patient-drug interactions to immunity, these initiatives aim to close critical knowledge gaps.
Learn more: bit.ly/4bElLiV
We’re proud to be part of the @globalhealthedctp3.bsky.social Stakeholders’ Group. Partnership is central to our work, and this group brings together experts dedicated to accelerating the clinical development of new or improved health technologies. Learn more 👉 bit.ly/4rIJhBd
The best research collaborations improve treatment for patients & strengthen the partners behind them. PAMAfrica undertook a portfolio of #malaria trials with efforts to strengthen research capacity for all partners. Read about the legacy of this Africa-Europe partnership: bit.ly/3PMe8PX
Cost and complexity put AI tools for drug discovery out of reach for many, but dd4gh is changing that. Watch Max Jakobs of @deepmirror.bsky.social explain how accessibility and pooled data can level the playing field for drug discovery researchers around the world.
Exchange programmes work best when expertise flows both ways. Meet Candice Soares de Melo & Jessica Thibaud, two South African researchers who spent time at MMV through the RAFIKI mentorship programme. See how the experience is shaping their work back home: bit.ly/4rMsltz
Next-gen #malaria prevention tools must be easy to administer & offer long-lasting protection. Long-acting injectables could provide at least 3 months of protection from a single dose. In Chicago, MMV & partners convened to align on the science & next steps 📸
When a child develops severe #malaria, every hour matters. This short film follows a mother’s journey to save her son, highlighting #SEMAReACT, a project working to improve access to treatment in hard-to-reach communities in DRC and Zambia. More info 👉 bit.ly/4b2YIiv
Floods don’t just destroy infrastructure; they create disease landscapes. Climate shocks in endemic areas are reshaping #malaria risks and threatening progress towards elimination. See why malaria must factor into extreme weather driven by #ClimateChange in @sciencex.bsky.social: bit.ly/46RPmUi
When #malaria prevention strategies reduce cases, the next question becomes: who else could benefit? After 5 years of delivering SMC to younger children, Uganda is expanding it to children up to age 10, a move supported by collaboration through the SMC Alliance 👉 bit.ly/46SaUAj
For many working to end #malaria, the fight is personal. Dr Manyando’s experience with severe malaria inspired her to make a difference for those most at risk. Now, she's leading the SEMA ReACT consortium to improve treatment for children in hard-to-reach communities. #IWD26
Clinical research has long treated pregnant women as a risk to be avoided. Yet exclusion increases risk, especially when #malaria during pregnancy can be deadly. On #IWD26, we call for protecting pregnant women through clinical trials, not from them: bit.ly/4u69dcc
Pregnant women are the group most impacted by #malaria after children. As a nurse treating malaria in pregnancy, Judith Ongeta contributed to the MiMBa pregnancy registry, gathering data on how medicines are used during pregnancy to inform treatment decisions & outcomes. #IWD26
When Dianah had #malaria during pregnancy, two lives were at risk, hers and her baby’s. For too long, pregnant & breastfeeding women have been excluded from research. Our MiMBa strategy is changing that. On #IWD26, we call for inclusive research that responds to the needs of all at-risk populations.
Team MMV, united in the fight for gender equity in #malaria research. Women are central to the fight: as patients, scientists and healthcare professionals. On #IWD26, we're celebrating the teams helping shape solutions and accelerating progress towards a malaria-free future.
Ahead of International Women's Day, we speak with Dr Delese Mimi Darko, Director General of the AMA
🗣️ ‘Women often face invisible barriers: limited access to networks, fewer sponsorships, and expectation to prove readiness.’
🔗 Interview: www.global-health-edctp3.europa.eu/news-and-eve...
#IWD2026
How can #malaria programmes navigate funding challenges? At last week’s SMC Alliance & Alliance for Malaria Prevention meeting, Catherine Pitt of @lshtm.bsky.social discussed the need to rethink funding decisions, using economic evaluations to prioritize impact: bit.ly/3P2LVUx
Leadership matters most when research needs to translate into action.
Congrats to Marcus Lacerda on his appointment as Director of @who.int TDR, where he’ll help advance the organization’s strategy of building locally driven research to address global health problems.
In case you missed it: new evidence on the value of investing in #malaria #innovation through MMV. Between 2000 and 2023, these investments delivered 13x their value in health benefits, with a 52% return per year. More people protected & more lives saved: bit.ly/4r59Ikm
When researchers gain access to new collaborations & expertise, the impact goes beyond a single project. Dr Cheuka shares how his work through our African call for proposals moved his team closer to identifying novel molecules for #malaria interventions: bit.ly/3MRp1ik
This week, the SMC Alliance and the Alliance for Malaria Prevention are holding a joint annual meeting in Kampala. Partners, including MMV, are sharing lessons and shaping the next phase of #malaria prevention through preventive medicines and insecticide-treated nets.
Marine sponges could hold the starting points for next-generation antimalarials. Dr Godwin Akpeko Dziwornu shares how his MMV-funded research is exploring sponge-derived compounds to inform #malaria drug discovery: bit.ly/3MRp1ik
Last call: MMV’s 23rd Call for proposals closes this Friday. Help us shape the next generation of #malaria meds. We’re looking for compounds addressing key prevention, treatment & elimination needs, including innovative biology beyond small molecules 👉 bit.ly/3XFUG8n
Malaria control is entering a new phase, with stronger country-led efforts key to protecting more people. A report from @malarianomore.org and @beatmalaria.bsky.social explores how data-driven planning, sustainable financing and partnerships can support country-led responses: bit.ly/4rgP6GJ
Long-term investment in #malaria innovation pays off in measurable ways. A @thelancet.com study (2000-2023) finds investments in MMV deliver 13× their value in health benefits. See why PDPs like MMV offer a proven model for global health investment: bit.ly/4aC2yhh
Time and cost are often the biggest barriers in early drug discovery, especially for researchers in endemic settings.
@suhealthsci.bsky.social postdoc Jessica Thibaud says MMV & @deepmirror.bsky.social’s dd4gh could change early-stage computational studies. 🎥
